Compare EVO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | SYRE |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.6B |
| IPO Year | 2021 | 2016 |
| Metric | EVO | SYRE |
|---|---|---|
| Price | $2.98 | $33.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $55.50 |
| AVG Volume (30 Days) | 107.8K | ★ 745.7K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $887,396,457.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.84 | $10.91 |
| 52 Week High | $5.10 | $35.31 |
| Indicator | EVO | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 68.01 |
| Support Level | $2.86 | $33.51 |
| Resistance Level | $3.09 | $35.31 |
| Average True Range (ATR) | 0.10 | 1.81 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 24.49 | 76.82 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.